BR112018073858A2 - métodos para tratamento de infecções pelo vírus da hepatite b usando inibidores de ns5a, ns5b ou ns3 - Google Patents
métodos para tratamento de infecções pelo vírus da hepatite b usando inibidores de ns5a, ns5b ou ns3Info
- Publication number
- BR112018073858A2 BR112018073858A2 BR112018073858-1A BR112018073858A BR112018073858A2 BR 112018073858 A2 BR112018073858 A2 BR 112018073858A2 BR 112018073858 A BR112018073858 A BR 112018073858A BR 112018073858 A2 BR112018073858 A2 BR 112018073858A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- ns5b
- ns5a
- inhibitors
- virus infections
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
a presente invenção refere-se a métodos para tratamento de infecções pelo vírus da hepatite b através da administração de um inibidor de ns5a, inibidor de ns5b, um inibidor de ns3 ou uma combinação dos mesmos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662342787P | 2016-05-27 | 2016-05-27 | |
US62/342,787 | 2016-05-27 | ||
PCT/US2017/032282 WO2017205078A1 (en) | 2016-05-27 | 2017-05-11 | Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018073858A2 true BR112018073858A2 (pt) | 2019-02-26 |
Family
ID=58745467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018073858-1A BR112018073858A2 (pt) | 2016-05-27 | 2017-05-11 | métodos para tratamento de infecções pelo vírus da hepatite b usando inibidores de ns5a, ns5b ou ns3 |
Country Status (13)
Country | Link |
---|---|
US (1) | US11738013B2 (pt) |
EP (1) | EP3463469B1 (pt) |
JP (2) | JP6770098B2 (pt) |
KR (1) | KR102202984B1 (pt) |
CN (1) | CN109414508A (pt) |
AU (1) | AU2017271990B2 (pt) |
BR (1) | BR112018073858A2 (pt) |
CA (1) | CA3025633C (pt) |
EA (1) | EA201892375A1 (pt) |
MA (1) | MA45088A (pt) |
MX (1) | MX2018014377A (pt) |
SG (1) | SG11201809893WA (pt) |
WO (1) | WO2017205078A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20211456T1 (hr) | 2014-12-26 | 2021-12-24 | Emory University | Protuvirusni derivati n4-hidroksicitidina |
CN111194217B (zh) * | 2017-09-21 | 2024-01-12 | 里伯赛恩斯有限责任公司 | 作为hcv rna复制抑制剂的4’-氟-2’-甲基取代的核苷衍生物 |
US11331331B2 (en) | 2017-12-07 | 2022-05-17 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
CN113038955A (zh) * | 2018-11-16 | 2021-06-25 | 公益财团法人东京都医学总合研究所 | 用于抑制乙型肝炎病毒复制的组合物 |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2726998T3 (es) | 2003-05-30 | 2019-10-11 | Gilead Pharmasset Llc | Análogos de nucleósidos fluorados modificados |
ATE516293T1 (de) | 2004-07-16 | 2011-07-15 | Gilead Sciences Inc | Antivirale verbindungen |
TWI389908B (zh) | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
TWI404537B (zh) | 2005-08-19 | 2013-08-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯 |
EP1957510A1 (en) | 2005-12-09 | 2008-08-20 | F.Hoffmann-La Roche Ag | Antiviral nucleosides |
CN102532198A (zh) | 2006-07-07 | 2012-07-04 | 吉里德科学公司 | 抗病毒的次膦酸酯化合物 |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
EA200971074A1 (ru) | 2007-06-29 | 2010-08-30 | Джилид Сайэнс, Инк. | Антивирусные соединения |
US8178491B2 (en) | 2007-06-29 | 2012-05-15 | Gilead Sciences, Inc. | Antiviral compounds |
PT2170888E (pt) | 2007-06-29 | 2015-08-21 | Gilead Sciences Inc | Purina derivados e sua utilização como moduladores de recetor de tipo toll 7 |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
DK2824100T3 (en) | 2008-07-08 | 2018-04-16 | Incyte Holdings Corp | 1,2,5-oxadiazoles as inhibitors of indolamine-2,3-dioxygenase |
US8242106B2 (en) | 2008-08-01 | 2012-08-14 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
NZ612380A (en) | 2008-12-09 | 2015-01-30 | Gilead Sciences Inc | Modulators of toll-like receptors |
CA2748034A1 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections |
PA8855601A1 (es) | 2008-12-23 | 2010-07-27 | Forformidatos de nucleósidos | |
AP3622A (en) | 2009-05-13 | 2016-03-02 | Gilead Sciences Inc | Antiviral compounds |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
EP2467377B1 (en) | 2009-08-18 | 2016-12-28 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
EP2467380B1 (en) | 2009-08-18 | 2016-11-30 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
PL2491035T3 (pl) | 2009-10-22 | 2018-01-31 | Gilead Sciences Inc | Pochodne puryny lub deazapuryny przydatne do leczenia (między innymi) infekcji wirusowych |
WO2011106106A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
SG184323A1 (en) | 2010-03-31 | 2012-11-29 | Gilead Pharmasett Llc | Stereoselective synthesis of phosphorus containing actives |
LT2578585T (lt) | 2010-05-31 | 2016-10-10 | Ono Pharmaceutical Co., Ltd. | Purinono darinys kaip btk kinazės inhibitorius |
RU2603467C2 (ru) | 2010-10-01 | 2016-11-27 | Вентиркс Фармасьютикалз, Инк. | Терапевтическое применение агониста tlr и комбинированная терапия |
CN103237549A (zh) | 2010-10-01 | 2013-08-07 | 帆德制药股份有限公司 | 过敏性疾病的治疗方法 |
TWI640526B (zh) | 2010-11-17 | 2018-11-11 | 基利法瑪席特有限責任公司 | 抗病毒化合物 |
CA2818853A1 (en) | 2010-11-30 | 2012-06-07 | Gilead Pharmasset Llc | 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus |
AR084217A1 (es) | 2010-12-10 | 2013-05-02 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
EP2663550B1 (en) | 2011-01-12 | 2016-12-14 | VentiRx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
US20140088085A1 (en) | 2011-01-12 | 2014-03-27 | Array Biopharma, Inc | Substituted Benzoazepines As Toll-Like Receptor Modulators |
LT2694484T (lt) | 2011-04-08 | 2018-10-10 | Janssen Sciences Ireland Uc | Pirimidino dariniai, skirti virusinių infekcijų gydymui |
UA114476C2 (uk) | 2011-05-18 | 2017-06-26 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Хіназолінові похідні для лікування вірусних інфекцій та подальших захворювань |
ME02196B (me) | 2011-11-16 | 2016-02-20 | Gilead Pharmasset Llc | Kondenzovani imidazolilimidazoli kao antiviralna jedinjenja |
SI2786996T1 (sl) | 2011-11-29 | 2017-02-28 | Ono Pharmaceutical Co., Ltd. | Hidroklorid s purinonskimi derivati |
EA037918B1 (ru) | 2011-12-21 | 2021-06-07 | Новира Терапьютикс, Инк. | Противовирусные агенты против гепатита в |
ES2716811T3 (es) | 2012-02-08 | 2019-06-17 | Janssen Sciences Ireland Unlimited Co | Derivados piperidinopirimidínicos para el tratamiento de infecciones víricas |
CN104144924B (zh) | 2012-03-31 | 2016-02-24 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗和预防乙型肝炎病毒感染的4-甲基-二氢嘧啶类 |
US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
PL2861604T3 (pl) | 2012-06-08 | 2017-08-31 | Gilead Sciences, Inc. | Makrocykliczne inhibitory wirusów flaviviridae |
WO2013185090A1 (en) | 2012-06-08 | 2013-12-12 | Gilead Sciences, Inc. | Macrocyclic inhibitors of flaviviridae viruses |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
US20140019288A1 (en) | 2012-07-13 | 2014-01-16 | Overall Parts Solutions, Inc. | Supply Chain Management System and Method |
NZ703731A (en) | 2012-08-10 | 2018-03-23 | Janssen Sciences Ireland Uc | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases |
SG10201605291WA (en) | 2012-08-28 | 2016-08-30 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
AU2013307328B2 (en) | 2012-08-28 | 2017-10-19 | Janssen Sciences Ireland Uc | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis B |
PE20150776A1 (es) | 2012-09-10 | 2015-05-21 | Hoffmann La Roche | 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b |
PL3023415T3 (pl) | 2012-10-02 | 2018-06-29 | Gilead Sciences, Inc. | Inhibitory demetylaz histonowych |
CN104837840B (zh) | 2012-10-10 | 2017-08-08 | 爱尔兰詹森科学公司 | 用于治疗病毒感染及其他疾病的吡咯并[3,2‑d]嘧啶衍生物 |
EA035431B1 (ru) | 2012-11-16 | 2020-06-15 | Янссен Сайенсиз Айрлэнд Юси | Гетероциклические замещенные производные 2-амино-хиназолина в качестве модуляторов tlr7 и/или tlr8 для лечения вирусных инфекций |
EP3763367A1 (en) | 2012-12-06 | 2021-01-13 | Celgene Quanticel Research, Inc. | Pyridine-pyrazole derivatives as histone demethylase inhibitors |
ES2658597T3 (es) | 2012-12-19 | 2018-03-12 | Celgene Quanticel Research, Inc. | Inhibidores de histona desmetilasa |
AU2013363957B2 (en) | 2012-12-21 | 2018-03-22 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
PL2950786T3 (pl) * | 2013-01-31 | 2020-05-18 | Gilead Pharmasset Llc | Formulacja skojarzona dwóch związków przeciwwirusowych |
AU2014220717B2 (en) | 2013-02-21 | 2018-03-29 | Janssen Sciences Ireland Uc | 2-aminopyrimidine derivatives for the treatment of viral infections |
JP6514117B2 (ja) | 2013-02-27 | 2019-05-15 | エピセラピューティクス アーペーエス | ヒストン脱メチル化酵素の阻害剤 |
HUE034820T2 (en) | 2013-02-28 | 2018-02-28 | Janssen Sciences Ireland Uc | Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B |
WO2014137929A1 (en) | 2013-03-04 | 2014-09-12 | Gilead Pharmasset Llc | Methods for treating hepatitis c virus |
CA2903473A1 (en) | 2013-03-12 | 2014-10-09 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
BR112015022545A2 (pt) | 2013-03-13 | 2017-07-18 | Constellation Pharmaceuticals Inc | compostos de pirazolo e os usos disso |
US9133166B2 (en) | 2013-03-14 | 2015-09-15 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
PL2970211T3 (pl) | 2013-03-15 | 2018-01-31 | Quanticel Pharmaceuticals Inc | Inhibitory demetylazy histonowej |
BR112015025052A2 (pt) | 2013-04-03 | 2021-07-06 | Janssen Sciences Ireland Uc | derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b |
PL2997019T3 (pl) | 2013-05-17 | 2019-03-29 | Janssen Sciences Ireland Uc | Pochodne sulfamoilotiofenamidu i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B |
BR112015028873A2 (pt) | 2013-05-17 | 2017-07-25 | Hoffmann La Roche | heteroaril-diidro-pirimidinas interligados na posição 6, para o tratamento e profilaxia de infecção pelo vírus da hepatite b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
AP2015008968A0 (en) | 2013-07-25 | 2015-12-31 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives andthe use thereof as medicaments for the treatment of hepatitis b |
EP3060547B1 (en) | 2013-10-23 | 2017-10-11 | Janssen Sciences Ireland UC | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
KR20160127714A (ko) | 2013-11-14 | 2016-11-04 | 노비라 테라퓨틱스, 인코포레이티드 | 아제판 유도체 및 b형 간염 감염의 치료 방법 |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
MX2016009828A (es) | 2014-01-30 | 2016-10-31 | Hoffmann La Roche | Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b. |
EA035848B1 (ru) | 2014-02-06 | 2020-08-20 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
EP3143020B1 (en) | 2014-05-13 | 2019-08-21 | F. Hoffmann-La Roche AG | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection |
KR101891933B1 (ko) | 2014-08-14 | 2018-08-24 | 에프. 호프만-라 로슈 아게 | B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 피리다존 및 트라이아진온 |
MX2017002451A (es) | 2014-08-27 | 2017-05-23 | Gilead Sciences Inc | Compuestos y metodos para inhibir histona desmetilasas. |
EP3204379B1 (en) | 2014-10-10 | 2019-03-06 | Genentech, Inc. | Pyrrolidine amide compounds as histone demethylase inhibitors |
US9637485B2 (en) | 2014-11-03 | 2017-05-02 | Hoffmann-La Roche Inc. | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection |
CN104546886A (zh) | 2014-12-12 | 2015-04-29 | 安徽一灵药业有限公司 | 一种雷迪帕韦与索非布韦复方包衣片制剂及其制备方法 |
-
2017
- 2017-05-11 JP JP2018561567A patent/JP6770098B2/ja active Active
- 2017-05-11 AU AU2017271990A patent/AU2017271990B2/en active Active
- 2017-05-11 WO PCT/US2017/032282 patent/WO2017205078A1/en unknown
- 2017-05-11 EP EP17725086.7A patent/EP3463469B1/en active Active
- 2017-05-11 CA CA3025633A patent/CA3025633C/en active Active
- 2017-05-11 KR KR1020187037210A patent/KR102202984B1/ko active IP Right Grant
- 2017-05-11 CN CN201780039972.3A patent/CN109414508A/zh active Pending
- 2017-05-11 SG SG11201809893WA patent/SG11201809893WA/en unknown
- 2017-05-11 US US16/304,824 patent/US11738013B2/en active Active
- 2017-05-11 MA MA045088A patent/MA45088A/fr unknown
- 2017-05-11 BR BR112018073858-1A patent/BR112018073858A2/pt not_active Application Discontinuation
- 2017-05-11 MX MX2018014377A patent/MX2018014377A/es unknown
- 2017-05-11 EA EA201892375A patent/EA201892375A1/ru unknown
-
2020
- 2020-09-24 JP JP2020159362A patent/JP2020203947A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN109414508A (zh) | 2019-03-01 |
KR20190010631A (ko) | 2019-01-30 |
EP3463469A1 (en) | 2019-04-10 |
JP2020203947A (ja) | 2020-12-24 |
MX2018014377A (es) | 2019-03-14 |
AU2017271990B2 (en) | 2019-12-19 |
EP3463469B1 (en) | 2023-12-13 |
KR102202984B1 (ko) | 2021-01-13 |
CA3025633A1 (en) | 2017-11-30 |
CA3025633C (en) | 2021-02-23 |
EA201892375A1 (ru) | 2019-08-30 |
SG11201809893WA (en) | 2018-12-28 |
MA45088A (fr) | 2019-04-10 |
JP2019519526A (ja) | 2019-07-11 |
US20220117952A1 (en) | 2022-04-21 |
US11738013B2 (en) | 2023-08-29 |
AU2017271990A1 (en) | 2018-11-29 |
WO2017205078A1 (en) | 2017-11-30 |
EP3463469C0 (en) | 2023-12-13 |
JP6770098B2 (ja) | 2020-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018071678A2 (pt) | compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv | |
BR112018009009A2 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
EA201890736A1 (ru) | Модуляторы корового белка вируса гепатита b | |
EA201691726A1 (ru) | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
EA201690452A1 (ru) | Ингибиторы полимеразы hcv | |
EA201691261A1 (ru) | Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b | |
CL2014003634A1 (es) | Inhibidores del virus de la hepatitis c | |
EA201890749A1 (ru) | ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ | |
CL2015003298A1 (es) | Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
EA201792182A1 (ru) | Композиции и способы для лечения анемии | |
EA201692010A1 (ru) | Фармацевтическое соединение | |
BR112018071048A2 (pt) | combinações e métodos que compreendem um inibidor da montagem de capsídeos | |
EA201792069A1 (ru) | Производные азокана и азонана и способы лечения инфекций гепатита в | |
BR112014030649A2 (pt) | inibidores macrocíclicos da flaviviridae vírus | |
EA201790758A1 (ru) | Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге | |
UY34570A (es) | Combinaciones de compuestos inhibidores de la proteína ns5a en el virus de hepatitis c | |
EA201890722A1 (ru) | Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге | |
BR112018073858A2 (pt) | métodos para tratamento de infecções pelo vírus da hepatite b usando inibidores de ns5a, ns5b ou ns3 | |
EA201890723A1 (ru) | Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге | |
EA201891666A1 (ru) | Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа | |
EA201592184A1 (ru) | 4'-фтор-2'-метилзамещенные нуклеозидные производные | |
EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
EA201791614A1 (ru) | Производные индола в качестве ингибиторов репликации вирусов денге | |
CY1123221T1 (el) | Ενωσεις θειαζολιδιου για αντιμετωπιση ιογενων λοιμοξεων | |
CY1118399T1 (el) | Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |